CITIUS PHARMACEUTICALS INC's ticker is CTXR and the CUSIP is 17322U207. A total of 39 filers reported holding CITIUS PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,220 | -43.0% | 50,000 | 0.0% | 0.01% | -44.4% |
| Q2 2023 | $60,000 | +2.6% | 50,000 | 0.0% | 0.01% | -10.0% |
| Q1 2023 | $58,500 | +48.1% | 50,000 | 0.0% | 0.01% | +42.9% |
| Q4 2022 | $39,500 | -35.2% | 50,000 | 0.0% | 0.01% | -46.2% |
| Q3 2022 | $61,000 | +32.6% | 50,000 | 0.0% | 0.01% | +44.4% |
| Q2 2022 | $46,000 | -48.9% | 50,000 | 0.0% | 0.01% | -35.7% |
| Q1 2022 | $90,000 | +16.9% | 50,000 | 0.0% | 0.01% | +27.3% |
| Q4 2021 | $77,000 | -24.5% | 50,000 | 0.0% | 0.01% | -38.9% |
| Q3 2021 | $102,000 | -41.4% | 50,000 | 0.0% | 0.02% | -40.0% |
| Q2 2021 | $174,000 | +95.5% | 50,000 | 0.0% | 0.03% | +87.5% |
| Q1 2021 | $89,000 | +74.5% | 50,000 | 0.0% | 0.02% | +60.0% |
| Q4 2020 | $51,000 | +96.2% | 50,000 | +100.0% | 0.01% | +66.7% |
| Q3 2020 | $26,000 | +73.3% | 25,000 | +25.0% | 0.01% | +100.0% |
| Q3 2019 | $15,000 | -77.9% | 20,000 | -50.0% | 0.00% | -85.7% |
| Q3 2018 | $68,000 | -26.1% | 40,000 | 0.0% | 0.02% | -25.0% |
| Q2 2018 | $92,000 | – | 40,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 314,000 | $559,000 | 0.11% |
| Inspire Advisors, LLC | 110,787 | $197,000 | 0.07% |
| Horst & Graben Wealth Management LLC | 49,590 | $88,000 | 0.03% |
| Freed Investment Group | 14,600 | $26,000 | 0.02% |
| GSA CAPITAL PARTNERS LLP | 57,465 | $102,000 | 0.02% |
| Miller Investment Management, LP | 50,000 | $89,000 | 0.02% |
| LMR Partners LLP | 63,950 | $114,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 50,356 | $90,000 | 0.00% |
| Renaissance Technologies | 989,096 | $1,761,000 | 0.00% |
| WILBANKS SMITH & THOMAS ASSET MANAGEMENT LLC | 20,000 | $36,000 | 0.00% |